258 related articles for article (PubMed ID: 32581286)
41. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
42. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yao Z; Gu B; Zhang Y; Qi J; Chen J; Xu Y; Chen F; Ma X; Miao M; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Yu L; Wu D; Wang Y
Bone Marrow Transplant; 2023 Jan; 58(1):103-105. PubMed ID: 36253466
[No Abstract] [Full Text] [Related]
43. [Prognostic analysis of allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in complete remission in the era of tyrosine kinase inhibitors].
Cao XY; Ma W; Zhang W; Liu DY; Zhao YL; Lu Y; Zhang JP; Zhou JR; Xiong M; Wei ZJ; Sun RJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):564-569. PubMed ID: 32810963
[No Abstract] [Full Text] [Related]
44. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
[TBL] [Abstract][Full Text] [Related]
45. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.
Gökbuget N; Dombret H; Giebel S; Bruggemann M; Doubek M; Foà R; Hoelzer D; Kim C; Martinelli G; Parovichnikova E; Rambaldi A; Ribera JM; Schoonen M; Stieglmaier JM; Zugmaier G; Bassan R
Hematology; 2019 Dec; 24(1):337-348. PubMed ID: 30757960
[TBL] [Abstract][Full Text] [Related]
46. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
47. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
48. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
49. [Allogeneic hematopoietic stem cell transplantation for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
Xu LP; Huang XJ; Liu KY; Chen H; Liu DH; Zhang YC; Chen YH; Han W; Gao ZY; Lu DP
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):231-5. PubMed ID: 15968308
[TBL] [Abstract][Full Text] [Related]
50. Clinical Utility of Droplet Digital PCR to Monitor BCR-ABL1 Transcripts of Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Post-chimeric Antigen Receptor19/22 T-Cell Cocktail Therapy.
Guan Y; Zhang M; Zhang W; Wang J; Shen K; Zhang K; Yang L; Huang L; Wang N; Xiao M; Zhou J
Front Oncol; 2021; 11():646499. PubMed ID: 33898316
[TBL] [Abstract][Full Text] [Related]
51. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
[TBL] [Abstract][Full Text] [Related]
52. [CAR T-cell bridging to allo-HSCT for relapsed/refractory B-cell acute lymphoblastic leukemia: the follow-up outcomes].
Yan M; Wu YJ; Chen F; Tang XW; Han Y; Qiu HY; Sun AN; Xue SL; Jin ZM; Wang Y; Miao M; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):710-715. PubMed ID: 33113601
[No Abstract] [Full Text] [Related]
53. Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis.
Xu X; Chen S; Zhao Z; Xiao X; Huang S; Huo Z; Li Y; Tu S
Front Oncol; 2021; 11():651944. PubMed ID: 34026627
[TBL] [Abstract][Full Text] [Related]
54. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
Tachibana T; Najima Y; Akahoshi Y; Hirabayashi S; Harada K; Doki N; Uchida N; Fukuda T; Sawa M; Ogata M; Takada S; Tanaka M; Matsuhashi Y; Tanaka J; Onizuka M; Ichinohe T; Atsuta Y; Kako S;
Ann Hematol; 2020 Oct; 99(10):2393-2404. PubMed ID: 32803312
[TBL] [Abstract][Full Text] [Related]
55. A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia.
Klisovic RB; Leung WH; Brugger W; Dirnberger-Hertweck M; Winderlich M; Ambarkhane SV; Jabbour EJ
Cancer; 2021 Nov; 127(22):4190-4197. PubMed ID: 34343354
[TBL] [Abstract][Full Text] [Related]
56. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia.
Chen H; Liu KY; Xu LP; Chen YH; Han W; Zhang XH; Wang Y; Qin YZ; Liu YR; Huang XJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1110-6. PubMed ID: 25698612
[TBL] [Abstract][Full Text] [Related]
57. Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Leukemia: 25 Years' Experience at Gustave Roussy Cancer Campus.
Chamseddine AN; Willekens C; De Botton S; Bourhis JH
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S129-40. PubMed ID: 26297265
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
[TBL] [Abstract][Full Text] [Related]
59. Donor-Derived CD7 CAR-T Therapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Acute T-Lymphocytic Leukemia Associated With Hepatitis B: A Case Report.
Li Z; Meng F; Li J; Wu T
Front Immunol; 2022; 13():931452. PubMed ID: 35903089
[TBL] [Abstract][Full Text] [Related]
60. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]